Robert Croop

Dr. Croop brings to Biohaven over 25 years of clinical drug development experience in a wide range of neuroscience programs. Board certified in Neurology by the American Board of Psychiatry and Neurology, he entered the pharmaceutical industry at DuPont Merck Clinical Research and Development. After joining Bristol-Myers Squibb through its acquisition of DuPont Pharma, he led a group responsible for First in Human, Phase I, and translational neuroscience clinical trials. More recently, he was a key member of the Eliquis (apixaban) Phase III clinical development and regulatory filing teams. His career includes successful marketing authorization applications for three New Chemical Entities with global approvals for multiple indications. A graduate of the University of Pennsylvania School of Medicine, he completed his internship in Medicine and residency in Neurology at the Hospital of the University of Pennsylvania.